The conversation in sleep supplements is shifting. If you're a brand manager or formulator, you've probably noticed something uncomfortable: the ingredient your sleep portfolio depends on — melatonin — is the same ingredient making headlines for quality and safety concerns.
We're not here to panic anyone. But we are tracking signals that every sleep-supplement buyer should understand before their next production run.
Part 1: Why Melatonin Is Facing Headwinds
The numbers are not the problem. The trend is.
- Pediatric melatonin ingestion reports rose 530% between 2012 and 2021, totaling 260,435 cases, with 2 deaths and 5 children requiring mechanical ventilation (Lelak K, et al., MMWR, 2022, PMID: 35653284).
- In 2025, FDA-commissioned testing of 25 retail melatonin gummies found actual content ranged from 0% to 667% of what the label claimed. Some products had zero melatonin. Others had nearly seven times the stated dose (Cohen PA, et al., JAMA, 2025, PMID: 39482109).
- Adverse-event surveillance data also include infant fatalities associated with melatonin exposure, though causality has not been established in all cases.
- USP is rewriting its melatonin monograph. When the pharmacopeia changes its testing standards, enforcement typically follows.
- Class-action exposure is growing. When a product category has documented label-accuracy failures ranging from 0% to 667%, plaintiff attorneys notice.
- Retail buyers are getting nervous. We're hearing from multiple supply chain contacts that some major retailers are quietly reviewing their melatonin supplement shelf policies.
Our view: Melatonin isn't going away overnight. But the risk profile of building a sleep portfolio around it is shifting — and not in your favor.
Part 2: What Glycine Actually Does (and Doesn't Do) for Sleep
Let's be honest: glycine is not "better melatonin." It's a completely different mechanism with a completely different evidence profile. If someone tells you glycine is a drop-in replacement for melatonin, they're overselling it.
The Mechanism
Glycine activates NMDA receptors in the suprachiasmatic nucleus — your brain's master clock. This triggers vasodilation, which lowers core body temperature during the night. Lower core temperature is one of the strongest physiological signals for sleep onset. This isn't exotic science. It's thermoregulation — the same reason a cool room helps you sleep. Glycine just helps your body get there chemically.
The Clinical Evidence
The most relevant human trial is Thomas et al. (2024, European Journal of Nutrition, PMID: 37874350): a randomized, double-blind crossover study in 14 physically active males. Collagen peptide supplementation (glycine-rich, ~15g/day) reduced nighttime awakenings from 29.3 to 21.3 events (P = 0.028). That's a meaningful result in a well-designed study. But let's be clear about the limitations:
- n = 14 (13 completers). Small sample. The crossover design helps, but this needs replication.
- Collagen peptides, not pure glycine. The study used collagen as the glycine delivery vehicle, so we're extrapolating somewhat to pure glycine supplementation.
- Young, healthy males. We don't know how this translates to older adults, women, or people with clinical sleep disorders.
A 2024 systematic review by Soh et al. (Geroscience, PMID: 39145678) concluded that glycine sleep benefits are promising but primarily derived from studies in populations with suboptimal sleep quality, and that meta-analysis was precluded by high heterogeneity across trials.
The honest evidence assessment: Small RCTs with positive results + well-characterized mechanism. Promising, not definitive. Stronger than "anecdotal," weaker than "large-scale clinical proof."
Commercial Translation
| Positioning | Status |
|---|---|
| Works well in combination sleep blends | ✅ Suitable |
| Suitable for "calm," "recovery," or "relaxation" positioning | ✅ Suitable |
| Mechanism is defensible in marketing copy (if worded carefully) | ✅ Suitable |
| Not strong enough as a standalone primary sleep ingredient | ⚠️ Limited |
| Cannot make comparative claims against melatonin | ❌ Avoid |
Part 3: The Ingredient Comparison That Actually Matters
Forget 15-row comparison tables. Here are the four dimensions that drive real procurement decisions:
| Dimension | Melatonin | L-Theanine | Glycine |
|---|---|---|---|
| Regulatory Landscape | Intensifying scrutiny — USP rewrite, FDA attention, documented quality failures | Novel Food status in some EU categories adds friction | Minimal — GRAS (US), no Novel Food issues (EU), globally accepted |
| Relative Cost per Dose | Premium — raw material concentration drives pricing | Moderate — established extraction supply chain | Lowest — commodity amino acid with multiple suppliers |
| Label-Accuracy Risk | High — the 0-667% problem is category-wide | Moderate — limited testing data | Low — standard amino acid assay, easy to verify |
| Portfolio Versatility | Sleep only | Sleep + cognitive | Sleep + joint + skin + cognitive + pet |
The "so what": If you're a procurement manager evaluating risk-adjusted cost, glycine is in a category of its own. It is an order of magnitude lower in cost per dose than melatonin, carries a fraction of the regulatory scrutiny, and serves multiple product categories from the same raw material. That's not a sales pitch — it's arithmetic.
Part 4: Where Glycine Genuinely Wins (and Where It Doesn't)
Wins
- Cost structure. Glycine is a commodity amino acid with multiple qualified suppliers. For brands operating at scale, this consolidates supplier relationships and reduces SKU complexity.
- Regulatory simplicity. GRAS in the US. No Novel Food friction in the EU. Widely accepted in Asia, Middle East, Latin America. For brands operating in 3+ jurisdictions, this saves months of compliance work.
- Multi-category leverage. The same glycine powder goes into sleep capsules, joint-health powders, beauty-from-within sachets, and pet calming treats.
- Taste. Glycine is mildly sweet. In functional gummies, beverages, or powder sachets, this is a genuine formulation advantage.
Doesn't Win
- Evidence depth. Melatonin has hundreds of RCTs. Glycine has a handful. If your customer base is science-literate and asks "where are the large trials?", you need an honest answer.
- Standalone potency. At 3g, glycine is a gentle nudge, not a knockout drop. It works best as part of a blend. Don't position it as "the sleep ingredient" — position it as "the foundation that makes your sleep blend work better."
- Consumer awareness. Most consumers have never heard of glycine for sleep. You'll need to educate. That's an investment, not a free ride.
Part 5: What Experienced Buyers Check (That Most Don't)
Not all glycine is identical. Specification quality and batch consistency vary significantly between manufacturers. Here's what sophisticated buyers verify:
- Particle size distribution. Glycine's flowability and compressibility vary with particle size. If you're making tablets or stick packs, ask for D10/D50/D90 data.
- Bulk density. Tapped vs. bulk density affects your capsule fill weight and sachet sizing. Ask for both. Typical range: 0.45–0.65 g/mL bulk density for supplement-grade glycine.
- Batch-to-batch consistency. Request COAs from 3 consecutive batches, not just the latest one. Purity should be ≥98.5% with minimal variation (±0.3% or less across batches).
- Residual solvents. Glycine is synthesized. Depending on the process, residual solvent levels (methanol, ethanol, acetone) should be below ICH Q3C limits. Most buyers don't ask. The good ones do.
- Supply chain redundancy. Does your supplier work with one factory or three? If your glycine comes from a single production line and that line goes down, your production stops.
Part 6: Supplier Evaluation Checklist
| What to Ask | Why It Matters | Target Spec | Red Flag |
|---|---|---|---|
| Purity (USP/EP/JP grade) | Baseline quality drives every downstream formulation decision | ≥98.5% | Anything below 98% |
| Particle size spec (D50 + range) | Formulation compatibility — impacts flowability, compressibility, blend uniformity | D50 with ± range | "We don't test that" |
| Bulk & tapped density | Capsule/sachet dosing accuracy | 0.45–0.65 g/mL | No data available |
| 3 consecutive batch COAs | Process consistency | ±0.3% purity variation max | Only latest batch provided |
| Residual solvent testing (ICH Q3C) | Safety & compliance | Below ICH Q3C limits | Not tested or not disclosed |
| Number of qualified production sites | Supply chain resilience | 2+ independent sites | Single-source with no backup |
| Certifications (GMP, HALAL, KOSHER, ISO 9001) | Market access | GMP + 2+ additional | Only ISO, no GMP |
| Sample policy | Willingness to be evaluated | Pre-qual samples available | Refuses pre-qual samples |
| Lead time & MOQ flexibility | Operational fit | ≤30 days, flexible MOQ | 90-day lead time, 20-ton MOQ only |
Part 7: The Bottom Line
Glycine isn't the next melatonin. It's a different ingredient with a different mechanism, a smaller evidence base, and a fundamentally different risk profile.
But that risk profile is exactly why it's worth paying attention to right now. In a market where the dominant ingredient is facing documented quality failures, regulatory rewrites, and rising legal exposure — an ingredient that costs an order of magnitude less, carries GRAS status, works across multiple categories, and has a defensible (if modest) clinical evidence base starts to look like a very sensible portfolio addition.
Not a silver bullet. A smart hedge.
References
- Lelak K, et al. (2022). Increase in Reported Adverse Events Associated with Melatonin Use in Children. MMWR. PMID: 35653284.
- Cohen PA, et al. (2025). Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. PMID: 39482109.
- Thomas DT, et al. (2024). Effect of Collagen Peptide Supplementation on Sleep in Physically Active Males. Eur J Nutr. PMID: 37874350.
- Soh K, et al. (2024). The effect of glycine administration on physiological systems in human adults: A systematic review. Geroscience. PMID: 39145678.
- Kumar P, et al. (2022). GlyNAC Supplementation in Older Adults. J Gerontol A Biol Sci Med Sci. PMID: 35975308.